Editorial
Nodding syndrome-we can now prevent it On Monday December 21, 2015, an information session was organized by the Ugandan Health minister Dr Elioda Tumwesigye in Pader district, northern Uganda, to explain the results of the investigations performed in Uganda to identify the cause of nodding syndrome (NS). 1 NS was first reported in Uganda in the districts of Kitgum, Pader, and Lamwo in 2009. Retrospective studies would suggest cases as early as 1997. By May 2014, a total of 3320 cases of NS had been registered and treated, as well as 5185 cases of epilepsy in the affected districts. NS is a form of atonic epilepsy. 2 Patients with NS present with episodes of uncontrollable nodding of the head (the head drops forward), mental retardation, and stunted growth, and often develop generalized convulsions. 3 The Ugandan Health minister informed the local population that NS was caused by onchocerciasis, probably through an autoimmune response triggered by an Onchocerca volvulus infection, the nematode causing river blindness. 1 Indeed many studies have now confirmed the association between NS, epilepsy, and onchocerciasis. [3] [4] [5] remains unclear whether these lesions were artefacts (myelin altered by fixation) or real brain lesions. A new post-mortem study that includes controls and with appropriate processing of brain tissue shortly after the death of the patient is needed to elucidate the pathophysiological mechanism of NS and onchocerciasisassociated epilepsy.
Prior to the NS outbreak in Uganda, only one post-mortem examination had been performed on a child who had died of a condition with similar clinical features as observed during an NS epidemic-Nakalanga syndrome. During examination of the child's brain, histological changes were observed in the adenohypophysis, but no deep-seated microfilariae.
14 Nakalanga syndrome was first described in 1950 among a population that had migrated to the Mabira Forest, close to the city of Jinja, on the east bank of the Nile in Uganda. 15, 16 Nakalanga syndrome is characterized by extreme growth retardation and the absence of external signs of sexual development; it is often but not always associated with epilepsy. 15, 16 Nakalanga features were later also reported from other onchocerciasis endemic foci, such as in West Uganda, 17 Burundi, 18 and Ethiopia. 19 In all these foci, the syndrome disappeared once onchocerciasis control was established. The hypothesis that blackflies are the cause of NS was proposed in a publication in the International Journal of Infectious Diseases in 2014 and it was suggested that these blackflies could potentially transmit a neurotropic virus. 20 Today this hypothesis seems very unlikely because the NS epidemic in northern Uganda stopped following the mass distribution of ivermectin and the treatment of the main rivers in the region, the Ashwa and the Pager, with larvicides. A recent case-control study in Titule, Bas Ué lé , an onchocerciasis endemic region in the Democratic Republic of the Congo (DRC), suggests that ivermectin has a protective effect on individuals for developing epilepsy. 21 In onchocerciasis hyperendemic regions, where ivermectin has not been introduced, the Contents lists available at ScienceDirect
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where ivermectin was distributed starting in 1994 but larviciding was never implemented, 67% of the patients with epilepsy were 20-29 years old in 2002. 23 This age shift in patients with epilepsy after the introduction of ivermectin suggests that ivermectin may reduce the incidence of epilepsy. Therefore, the pathophysiological mechanism causing NS and other forms of epilepsy in onchocerciasis endemic regions is probably directly or indirectly related to the O. volvulus infection.
NS should be considered only the 'ears of the hippo', the hippo being onchocerciasis-associated epilepsy. 4 Indeed NS and other forms of epilepsy appear clustered in specific villages and also within households in onchocerciasis endemic regions. 26 An explanation for this may be that parasite antigen exposure during prenatal or neonatal life may depress the parasite-specific cellular immune responses in these children. [26] [27] [28] The in utero transmission of O. volvulus has also been described. 29 Other children, less exposed to O. volvulus and/ or exposed later in life, may develop only tonic-clonic epilepsy with minimal or no mental retardation and no diminished growth or sexual development. The reason for the epidemic of NS/epilepsy in northern Uganda and South Sudan is likely related to living conditions during the war. In northern Uganda, beginning in 1996, hundreds of thousands of people were put into internally displaced persons camps, some of them very close to large rapid flowing rivers infested with O. volvulus-infected blackflies. In such camps, people were living in households very close to each other. At that time there was no mass drug administration of ivermectin in northern Uganda in the Kitgum and Pader districts and this probably resulted in an increasing number of O. volvulus infestations in children with a weak immune system caused by malnutrition and co-infections. These O. volvulus infestations were followed by an epilepsy epidemic. The onchocerciasis hyper-endemicity in the region was shown in 2009, when in a case-control study microfilariae were observed in skin snips from 71% of patients with epilepsy and 54% of controls. 5 Before the war, herds of cattle in Kitgum and Pader were stolen by the Karamajong (a tribe from north-east Uganda), and the remaining cattle were eaten by rebels roaming the areas during the start of the war (late 1980s). Blackflies of the species Simulium bovis normally bite cows and transmit Onchocerca dukei (a cattle parasite closely related to O. volvulus), but they also bite humans in this area, particularly those herding cattle. Simulium damnosum s.l. is the main vector transmitting O. volvulus, but this also bites cows and can transmit Onchocerca ochengi (another closely related cattle parasite). Humans are not known to develop any infection when exposed to the bites of blackflies infected with either O. dukei or O. ochengi, but they may develop antibodies against these cattle Onchocerca nematodes that may protect them against O. volvulus-related disease (or modulate the immune response in other ways). 30 It is possible that during the war, the disappearance of the cows resulted in a decreased associated immunity against O. 32 and naturally. 33 The protective effect of O. ochengi antibodies against O. volvulus infection may explain why in Western Equatoria Province of South Sudan, an onchocerciasis endemic area with a high prevalence of NS, the Dinkas, who are cattle keepers, were reported to be less likely to develop NS. 34 Action is urgently needed because onchocerciasis-associated epilepsy is catastrophic for entire villages. Many affected children not only suffer from epilepsy, but also dementia and psychiatric problems. 35 Caretakers are left desperate and living in fear of leaving their affected children alone, because some children simply wander away, disappear, and die a lonely and tragic death mostly due to burns or drowning. Many affected children drop out of school and lack access to quality patient care. Since the start of ivermectin distribution and larvicide treatment of rivers in Uganda, the NS epidemic has declined dramatically. In contrast, the situation continues to worsen in South Sudan because there is very little distribution of ivermectin and no larviciding of rivers in this country. Moreover, anti-epileptic treatment is generally not available in the affected villages.
The burden of disease caused by onchocerciasis-associated epilepsy remains to be determined. A high prevalence of epilepsy has been observed in most onchocerciasis endemic regions with low coverage of ivermectin. 4, 36, 37 If 1% of the 36 million people with O. volvulus infection (equivalent to the approximate excess prevalence of epilepsy over non-endemic areas 38 ) were to develop epilepsy, the number of excess cases of epilepsy due to onchocerciasis would be in the order of 360 000. 4 This excess in prevalence of epilepsy may be preventable by increasing the coverage of ivermectin treatment. The fact that O. volvulus increases the risk of epilepsy should be used as an additional argument to strengthen onchocerciasis elimination plans and motivate individuals to take the ivermectin at least annually. Uganda has shown that providing symptomatic care, mainly through timely consumption of anti-epilepsy drugs coupled with proper nutrition, can achieve big improvements in patient outcomes. 39 In Uganda, many children even manage to go back to school thanks to such treatment. A lot of scientific progress has been made recently. We have learned that improved onchocerciasis control will stop onchocerciasis-associated epilepsy including NS. We have also learned from rehabilitation centres in Uganda that NS is a manageable disease. 40 The main challenge today is how to scale up and improve the treatment of patients suffering from onchocerciasis-associated epilepsy in all affected onchocerciasis regions of Africa. To deal with this challenge we should learn from the experience gained with the scaling up of HIV treatment in Africa. Similarly, for onchocerciasis-associated epilepsy, we will need to apply advocacy, fighting ignorance and misconceptions, provide uninterrupted free access to anti-epileptic treatment, including cheap and more effective anti-epileptic drugs, and provide decentralized services to diagnose and treat epilepsy early and to monitor treatment adherence, a public health approach that includes task shifting, training of primary and lower level health care workers, and working with communities. The problem is that onchocerciasisassociated epilepsy occurs in remote rural areas of Africa and involves very poor populations, often in zones where the health system is very weak and where there has been war or there is instability. Moreover, this is not an illness that threatens the industrialized world. Similar to the fight against AIDS, to reach the goal of elimination of onchocerciasis-associated epilepsy will require partnerships between scientists, communities and advocacy groups, health care workers, ministries of health, nongovernmental organizations, the pharmaceutical industry, and funding organizations.
Funding: The work of R. Colebunders is funded by a 2014ADG/ ERC grant (No. 671055).
Conflict of interest: No conflict of interest to declare.
